Liu Zhaoyun, Han Mei, Ding Kai, Fu Rong
Department of Hematology, Tianjin Medical University General Hospital Tianjin 300052, P. R. China.
Am J Cancer Res. 2020 Dec 1;10(12):4085-4097. eCollection 2020.
Pim kinase, which has three isozymes (Pim-1, Pim-2 and Pim-3), is a serine/threonine kinase abnormally expressed in many cancers. High Pim kinase expression has been recognized to be associated with disease progression and prognosis. It is well accepted that Pim kinase is considered a clinical biomarker and potential therapeutic target for tumor cell. In recent years, researches verified the role of Pim kinase in immunomodulation. The mechanisms by which Pim kinase modulates the immune microenvironment and regulates immune cells, as well as the effects of Pim kinase inhibitors on immunity, have not been systematically described. This review comprehensively focuses on the current research status of Pim kinase pathways and the immune regulation.
Pim激酶有三种同工酶（Pim-1、Pim-2和Pim-3），是一种在多种癌症中异常表达的丝氨酸/苏氨酸激酶。Pim激酶高表达已被认为与疾病进展和预后相关。人们普遍认为Pim激酶是一种临床生物标志物和肿瘤细胞的潜在治疗靶点。近年来，研究证实了Pim激酶在免疫调节中的作用。Pim激酶调节免疫微环境和免疫细胞的机制，以及Pim激酶抑制剂对免疫的影响，尚未得到系统描述。本综述全面聚焦于Pim激酶信号通路和免疫调节的当前研究现状。
